THOROLD, ON, Sept. 28, 2015 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 15 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA. Data from comparisons of these kits with similar kits on the market clearly indicates that Norgen’s kits yield significantly more diverse cfcRNA, owing to the fact that Norgen’s kits use a proprietary resin technology that has the ability to bind all RNA sequences irrespective of size or GC content. The sensitivity and speed of these novel kits make them very powerful tools for a number of applications including the sensitive detection of tumor biomarkers and viruses, microRNA detection by PCR, quantitative PCR, RT-PCR, microarrays, Next Gen Sequencing, etc.
Norgen’s blood/plasma/serum and urine kits utilize a convenient spin column format for NA purification from both fresh and frozen samples. In particular, the circulating NA kits provide a major advantage over other available kits in that they isolate significantly more diverse, inhibitor-free cfcRNA than any other technology on the market. Circulating NA present in 10 µL to 10 mL plasma inputs or 250 µL to 30 mL of urine inputs are [click to continue…]
For more information please read the letter of the special issue editor:
MicroRNA is a short non-coding RNA whose primary function is supposed to be post-transcriptional regulation of mRNAs. Although it has been extensively studied for over a decade, its detailed mechanisms have not yet been fully understood. The difficulty is possibly because of lack of experimentally and theoretically effective methods, and this should be solved by invention of new technologies. Thus, any new proposals regarding them are welcomed. In addition to these, many new aspects, e.g., coordinated actions of microRNA with various epigenetic factors, including promoter methylations, histone modifi cations, and structures of chromosome, have started to pique researchers’ interests. Furthermore, non-canonical functions, e.g., functionalities inside nuclei and non-canonical bindings, also seem to be important. In conclusion, any research papers about new theoretical, computational, or experimental methodologies, as well as excellent reviews regarding these topics are welcomed. MicroRNA regulations, of not only target genes, but also any pathways, diseases, or differentiation, are also interesting topics. We are looking forward to receiving many submissions from outstanding expert on these topics.
The report, entitled ‘Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities’, exemplifies the successful use of microRNA prediction analysis, bioinformatic data mining, and in vitro and ex vivo experimentation to discover and validate novel molecular players in prostate cancer. Using microarray gene expression analysis of matched tumor and adjacent normal prostate tissue from AA and EA cancer patients, Wang et. al. identified hundreds of altered microRNAs and mRNAs in prostate cancer. TargetScan, coupled with the Global Test and Gene Set Enrichment Analysis algorithms, identified dozens of predicted miRNA-mRNA pathways in which both genes were found to be [click to continue…]
Dramatic Response with Novel microRNA Replacement Therapy in Malignant Pleural Mesothelioma Published in the American Journal of Respiratory and Critical Care Medicine
NEW YORK and SYDNEY, June 15, 2015 /PRNewswire/ – EnGeneIC Ltd, an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that, together with the Asbestos Diseases Research Institute (ADRI), a patient case study from the MesomiR-1 Phase 1 clinical trial of its EDV™ nanocells packaged with a miR-16-based microRNA for the treatment of malignant pleural mesothelioma (MPM) has been published in the peer-reviewed journal American Journal of Respiratory and Critical Care Medicine.
The case study, titled, “A significant metabolic and radiological response following a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma,” reported on the remarkable results of a 51-year old male who was diagnosed with MPM in May 2013. After eventually failing three chemotherapy regimens, he entered the MesomiR-1 study. The patient was one of the six patients recruited into the first cohort, which received eight weekly infusions of 5×109 EDV™ nanocells packaged with miR-16a, coined TargomiRs for this study.
At the end of the eight-week study period, a near-complete response was evident on the patient’s PET and CT scans, and which was confirmed four weeks later. In addition, the patient had a significant improvement [click to continue…]
Achieves Key ‘Clinical Map Initiative’ Goal for 2015 and Advances Orphan Disease Efforts LA JOLLA, Calif., June 4, 2015 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically […]
If you are traveling to New Orleans to attend IMMUNOLOGY 2015 you might be interested in the following workshop next Monday, May 11th: Recent Work & Current Methods in Immunology microRNA Research May 11, 2015 – 11:15 AM-12:00 PM – Exhibit Hall Workshop Room #1 There is now strong evidence suggesting that miRNA signaling plays a […]
Series D is Mirna’s Largest Financing to Date With Ten Institutional and Strategic Investors AUSTIN, TX–(Marketwired – April 30, 2015) - Mirna Therapeutics (Mirna), a private, clinical-stage biopharmaceutical and immuno-oncology company focused on the development of microRNA-based cancer therapeutics, today announced the completion of a $41.8 million Series D financing. The company’s second institutional financing was […]
SANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ – SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA. There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and […]
-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca- -RG-125 (AZD4076) is Regulus’ 3rd Clinical Candidate, Achieving Key ‘Clinical Map Initiative’ Goal for 2015- LA JOLLA, Calif., April 7, 2015 /PRNewswire/ – Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR […]